Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled time : 15:00 save search
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
Published: 2024-03-28 (Crawled : 15:00) - prnewswire.com
ALPMY | News | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 0.82%
H: 0.0%
C: -2.54%
keytruda license bladder cancer treatment medical application advanced
Radiopharmaceuticals Market to Reach $11.6 Billion by 2034 as Cancer Treatment Gains Traction - Future Market Insights, Inc.
Published: 2024-03-25 (Crawled : 15:00) - prnewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.08%
H: 0.15%
C: -0.44%
LLY | News | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.06%
H: 0.96%
C: 0.26%
CAH | $106.0 -0.49% -0.94% 1.5M
|
Distribution Services
|
| O: 0.02%
H: 0.73%
C: -0.02%
LNTH | $62.34 1.4% 1.38% 1.3M
|
Health Technology
|
| O: 0.1%
H: 1.98%
C: -0.08%
reach cancer treatment market
Regeneron Hit With Two CRLs, J&J’s PAH Treatment Approved
Published: 2024-03-25 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
PRGO | $29.94 -0.33% 0.0% 970K
|
Health Technology
|
| O: 0.35%
H: 0.35%
C: -1.34%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
ABT | News | $105.27 -0.6% -0.15% 7.3M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: 0.0%
approved treatment
MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders
Published: 2024-03-05 (Crawled : 15:00) - biospace.com/
MAIA | $1.96 -1.01% 0.0% 68K
|
|
| O: -3.45%
H: 10.71%
C: 5.71%
ceo cancer pipeline treatment
IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024
Published: 2024-03-04 (Crawled : 15:00) - biospace.com/
ICCM | $1.24 -3.88% -4.03% 110K
|
Manufacturing
| Email alert
Add to watchlist
prosense treatment alternative study
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
Published: 2024-02-14 (Crawled : 15:00) - biospace.com/
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.23%
H: 0.44%
C: 0.14%
drug review food tumors treatment application advanced
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne)
Published: 2024-02-13 (Crawled : 15:00) - biospace.com/
EWTX | $15.43 -1.41% -1.43% 530K
|
Manufacturing
|
| O: -2.9%
H: 2.99%
C: 2.77%
edg-5506 fda treatment designation duchenne
FDA Decisions: Agency Greenlights Takeda's Oral EoE Treatment in Company's Second Straight Win
Published: 2024-02-12 (Crawled : 15:00) - biospace.com/
PRGO | $29.94 -0.33% 0.0% 970K
|
Health Technology
|
| O: 0.31%
H: 1.44%
C: 1.31%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
ABT | News | $105.27 -0.6% -0.15% 7.3M
|
Health Technology
|
| O: -0.64%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
fda treatment
Synthekine Announces Strategic Collaboration with Sanofi to Develop Selective IL-10 Agonists for Treatment of Inflammatory Diseases
Published: 2024-01-29 (Crawled : 15:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
il-10 treatment collaboration sanofi
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
TEVA | $12.78 -3.03% -0.24% 9M
|
Health Technology
|
| O: -0.52%
H: 3.73%
C: 1.87%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.09%
H: 0.0%
C: 0.0%
disease treatment collaboration teva deal
LHC Group Gets Center-Stage Treatment At UnitedHealth Group’s Investor Day
Published: 2023-11-30 (Crawled : 15:00) - lhcgroup.com
LHCG | $169.81 0.47% -0.03% 0
|
Health Services
| Email alert
Add to watchlist
day group treatment
FDA Decisions: First Treatment for Desmoid Tumors and a Dry Eye Rejection for Aldeyra
Published: 2023-11-28 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -1.89%
H: 0.02%
C: 0.02%
PRGO | $29.94 -0.33% 0.0% 970K
|
Health Technology
|
| O: 0.78%
H: 0.81%
C: -1.71%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
ABT | News | $105.27 -0.6% -0.15% 7.3M
|
Health Technology
|
| O: -0.24%
H: 0.03%
C: -0.39%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -1.41%
H: 0.87%
C: 0.0%
fda tumors treatment eye
Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting
Published: 2023-11-02 (Crawled : 15:00) - biospace.com/
LEGN | $47.16 -3.42% -3.54% 820K
|
Health Technology
|
| O: 0.52%
H: 0.28%
C: -3.54%
biotech treatment meeting
A Differentiated DMD Treatment and Two New Ulcerative Colitis Therapies
Published: 2023-10-27 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -18.18%
H: 0.0%
C: 0.0%
PRGO | $29.94 -0.33% 0.0% 970K
|
Health Technology
|
| O: -0.35%
H: 0.14%
C: -5.2%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -2.35%
H: 0.0%
C: 0.0%
ABT | News | $105.27 -0.6% -0.15% 7.3M
|
Health Technology
|
| O: 1.57%
H: 0.6%
C: -2.01%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -15.73%
H: 0.0%
C: 0.0%
treatment dmd
Global Radiofrequency Ablation Devices Market Set to Reach $8.18 Billion by 2030: Transforming Treatment for Cardiovascular Diseases and Cancer
Published: 2023-10-16 (Crawled : 15:00) - prnewswire.com
SNNUF | $11.93 -1.12% 710
|
Health Technology
|
| O: 1.69%
H: 0.0%
C: 0.0%
MDT | News | $79.19 0.14% 0.0% 6.1M
|
Health Technology
|
| O: 0.26%
H: 0.82%
C: -0.55%
CNMD | $71.08 -2.31% 0.0% 620K
|
Health Technology
|
| O: 1.35%
H: 1.31%
C: 0.55%
BSX | $67.42 -0.8% -0.53% 5.9M
|
Health Technology
|
| O: 0.59%
H: 1.63%
C: 0.58%
ABT | News | $105.27 -0.6% -0.15% 7.3M
|
Health Technology
|
| O: 0.25%
H: 1.93%
C: 1.19%
CNMD | $71.08 -2.31% 0.0% 620K
|
Health Technology
|
| O: 1.35%
H: 1.31%
C: 0.55%
reach cancer treatment global set cardiovascular market
TG Therapeutics Announces Presentation of Data for BRIUMVI at the 2023 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting
Published: 2023-10-11 (Crawled : 15:00) - globenewswire.com
TGTX | $14.0 1.3% 1.29% 3.5M
|
Health Technology
|
| O: 2.97%
H: 1.7%
C: -4.46%
briumvi presentation sclerosis treatment research meeting therapeutics
Coya Therapeutics Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting
Published: 2023-10-05 (Crawled : 15:00) - biospace.com/
COYA | $8.53 3.52% 3.4% 30K
|
|
| O: 0.0%
H: 13.48%
C: 2.42%
als sclerosis treatment meeting therapeutics
Acasti Pharma to Host KOL Event on GTX-104: A Potential New Treatment Standard for Rare and Life-Threatening aneurysmal Subarachnoid Hemorrhage (aSAH)Virtual Webinar to Take Place October 11, 2023 at 2:00pm ET
Published: 2023-10-04 (Crawled : 15:00) - biospace.com/
ACST | $3.07 -3.76% -3.91% 9.3K
|
Health Technology
|
| O: -0.75%
H: 5.3%
C: -1.89%
gtx-104 rare pharma treatment potential
Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Published: 2023-10-02 (Crawled : 15:00) - biospace.com/
RCKT M | $23.44 -1.01% -1.02% 550K
|
Health Technology
|
| O: 0.29%
H: 0.0%
C: -5.35%
fda license review treatment pharmaceuticals application
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
Published: 2023-09-28 (Crawled : 15:00) - globenewswire.com
FOLD F | $10.35 -1.9% -1.93% 1.7M
|
Health Technology
|
| O: -1.32%
H: 1.73%
C: -6.69%
fda disease approval treatment therapeutics
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.